Biopharmaceutical stocks are slated to end the year on a sour note. This industrywide sell-off has also picked up momentum during the waning days of Nov., with an eye-popping 358 biopharma stocks falling by more than 10% during just the past three weeks. Savvy investors, though, know that steep drops in the market typically represent compelling buying opportunities.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting